Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - CTI BIOPHARMA CORP | Financial_Report.xls |
10-Q - FORM 10-Q - CTI BIOPHARMA CORP | d357343d10q.htm |
EX-32 - SECTION 906 CEO AND CFO CERTIFICATION - CTI BIOPHARMA CORP | d357343dex32.htm |
EX-31.1 - SECTION 302 CEO CERTIFICATION - CTI BIOPHARMA CORP | d357343dex311.htm |
EX-10.7 - LETTER OF GUARANTEE BETWEEN REGISTRANT AND QUINTILES COMMERICAL EUROPE LIMITED - CTI BIOPHARMA CORP | d357343dex107.htm |
EX-10.5 - DIRECTOR COMPENSATION POLICY - CTI BIOPHARMA CORP | d357343dex105.htm |
EX-10.6 - MASTER SERVICES AGREEMENT DATED JULY 9, 2012 - CTI BIOPHARMA CORP | d357343dex106.htm |
EX-31.2 - SECTION 302 CFO CERTIFICATION - CTI BIOPHARMA CORP | d357343dex312.htm |
Exhibit No. 15
August 2, 2012
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report dated August 2, 2012 on our review of interim financial information of Cell Therapeutics, Inc. for the six month period ended June 30, 2012 included in the Companys quarterly report on Form 10-Q for the quarter ended June 30, 2012 is incorporated by reference in the Registration Statements of Cell Therapeutics, Inc. on Forms S-3 (File Nos. 333-130411, 333-131533, 333-130004, 333-36038, 333-41300, 333-67906, 333-36603, 333-38431, 333-108926, 333-112681, 333-138170, 333-134126, 333-143452, 333-149980, 333-149981, 333-149982, 333-152171, 333-160969, 333-158272, 333-157376, 333-153358, 333-163479, 333-161442, 333-93835, 333-33872, 333-33268, 333-39385, 333-177506 and 333-182330) and on Form S-8 (File No. 333-65200, 333-58957, 333-35919, 333-97015, 333-106568, 333-106571, 333-112791, 333-118016, 333-146624, 333-152168, 333-158260, 333-162955, 333-170044 and 333-178158).
Yours very truly,
/s/ Marcum LLP
San Francisco, California